|Bid||0.00 x 1000|
|Ask||0.00 x 1100|
|Day's Range||144.38 - 148.25|
|52 Week Range||117.58 - 212.00|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 27, 2022 - May 02, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||208.20|
Foreign direct investments play an important role as an indicator of a healthy economy in terms of economic growth and long-term capital movement.
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings. Canada approves Amylyx drug Amylyx Pharmaceuticals Inc. (Nasdaq: AMLX) scored its first-ever approval from Health Canada for its amyotrophic lateral sclerosis (ALS) drug Albrioza.
The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.